Addressing inherited degenerative diseases by designing a new class of small-molecule genomic medicines
Employees: 11-50
Total raised: $170M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 20.02.2021 | Logos Capi... | logoscapit... |
| - | Avoro Capi... | avorocapit... |
| - | RA Capital... | racap.com |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.01.2021 | Series B | $125M | - |
| 24.03.2020 | Series A | $45M | - |
Mentions in press and media 11
| Date | Title | Description |
| 14.05.2026 | Cramer’s lightning round: Buy BillionToOne | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. Silicon Motion Technology: “We like SIMO. I... |
| 12.05.2021 | DESIGN THERAPEUTICS, INC. Design Therapeutics : Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development (Fo... | Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development Company On-track to Initiate Phase 1 Clinical Trial for the Treatment of Friedreich Ataxia i... |
| 23.03.2021 | Design Therapeutics plans to raise up to $240M in IPO | Biotech company Design Therapeutics has set terms to raise as much as $240 million in its IPO. The company plans to sell 12 million shares for between $18 and $20 each in the offering. Design's top shareholders include SR One (10% post-IPO ... |
| 27.01.2021 | Design Therapeutics Picks Up $125M For Small Molecules | San Diego-based Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B fundin... |
| 27.01.2021 | Design Therapeutics Secures $125 Million in Series B | SAN DIEGO--(BUSINESS WIRE)--Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, to... |
| 27.01.2021 | Design Therapeutics has secured a $125M Series B to advance their pipeline of genomic medicines for nucleotide repeat expansion disorders | - |
| 24.03.2020 | Design Therapeutics Finds $45M | San Diego-based Design Therapeutics, which is developing therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions, has raised $45M in a Series A financing round. The round was led by SR One, and also... |
| 24.03.2020 | Design Therapeutics has raised a $45M Series A to develop a new class of disease-modifying therapies for serious degenerative disorders | - |
| 24.03.2020 | Design Therapeutics Pulls In $45M Series A | SAN DIEGO, CA, Design Therapeutics announced today a $45 million Series A financing. >> Click here for more funding data on Design Therapeutics >> To export Design Therapeutics funding data to PDF and Excel, click here De... |
| 24.03.2020 | Design Therapeutics Raises $45M in Series A Funding | Design Therapeutics, a San Diego, CA-based developer of a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions, closed a $45m Series A financing. The round was led by SR One, with pa... |
Show more